Sodium Iodide
CAS 7681-82-5
Sodium Iodide (CAS 7681-82-5) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 236 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 49000 nM | 2 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Sodium Iodide | 9884 | SU | MTHSPL |
| SODIUM IODIDE | 9884 | SU | MTHSPL |
| sodium iodide | 9884 | SU | MTHSPL |
| sodium iodide | 9884 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sodium Iodide used for in pharmaceutical contexts?
Sodium Iodide (CAS 7681-82-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sodium Iodide?
Sodium Iodide has 236 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Activated partial thromboplastin time prolonged, Anaemia, Analgesic therapy, Antacid therapy, Anticoagulant therapy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sodium Iodide also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Iodide with EU status "permitted".
What clinical phase is Sodium Iodide in?
Sodium Iodide is rendered with ChEMBL max phase 4 (approved).